Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft-Reference-Cited by-同舟云学术

Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft

Published:2021-02-13 Issue:4 Volume:35 Page:514-522
ISSN:0914-7187
Container-title:Annals of Nuclear Medicine
language:en
Short-container-title:Ann Nucl Med

Author:

Gu Wenchao,Yudistiro Ryan,Hanaoka Hirofumi^ORCID,Katsumata Natsumi,Tsushima Yoshito

Funder

JSPS KAKENHI grant

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12149-021-01597-5.pdf

Reference31 articles.

1. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin’s lymphoma. Int J Radiat Oncol. 2004;59:1274–87.

2. Read ED, Eu P, Little PJ, Piva TJ. The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma. Target Oncol. 2015;10:15–26.

3. Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576–88.

4. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757–78.

5. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126–36.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radionuclide therapy of bevacizumab-based PNA-mediated pretargeting;Nuclear Medicine Communications;2024-07-16

2. Advances in post-translational modifications of proteins and cancer immunotherapy;Frontiers in Immunology;2023-08-22

3. Nanobiotechnology‐mediated radioimmunotherapy treatment for triple‐negative breast cancer;MedComm – Biomaterials and Applications;2023-03

4. A review of the mechanism of succinylation in cancer;Medicine;2022-11-11

5. Present and future of target therapies and theranostics: refining traditions and exploring new frontiers—highlights from annals of Nuclear Medicine 2021;European Journal of Nuclear Medicine and Molecular Imaging;2022-07-23